| abstract |
Drugs for the treatment and/or prevention of brain diseases, containing as the active ingredient compounds represented by the general formula (I) or pharmaceutically acceptable salts thereof, wherein R is hydrogen, C1-C8 alkyl, substituted C1-C8 alkyl, aryl, substituted aryl, aryl-substituted C1-C8 alkyl, or the like; Y is hydrogen or -C(R2)R3 (wherein R?2 and R3¿ are each hydrogen, C¿1?-C8 alkyl, alkoxy(C1-C8) alkyl(C1-C8), hydroxyalkyl(C1-C8), or the like), with the proviso that when Y is hydrogen, a represents a single bond, while when Y is -C(R?2)R3¿, a represents a double bond; -A-B- is -CH¿2?-CH2-, -S-CH2-, -O-CH2-, -CH2-S-, -CH2-O-, -SO-CH2-, -CH2-SO-, -SO2-CH2-, or -CH2-SO2-; and Z is -CH2- or a single bond. |